The content on this site is intended for healthcare professionals only
Prof Kröger talks to ecancertv at ICMM 2016 about the standard treatment of multiple myeloma in younger patients.
In particular, he highlights both the benefits and complications associated with allogeneic stem cell transplants.
ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
Lower levels of inflammatory markers and tumour burden is linked to improvements in PFS with Ide-Cel in R/R multiple myeloma
Treatment of multiple myeloma in Turkey
PTCy/Tac/MMF new standard for GVHD prophylaxis in reduced intensity conditioning
Polatuzumab vedotin combined with R-ICE as second-line therapy gives favourable results against R/R diffuse large B-cell lymphoma
